New combo tackles breast cancer in the liver

NCT ID NCT06860815

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining an immunotherapy drug (cemiplimab) with a radiation treatment (Y90 radioembolization) can help people whose breast cancer has spread to the liver. The treatment aims to boost the immune system to attack tumors while also delivering radiation directly to the liver. The study will enroll 11 adults with stage IV breast cancer that is mainly in the liver.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (immunotherapy drug) and yttrium-90 SIR-Spheres (radioactive microspheres)
What this could lead to: If it works, this could point toward a new combination treatment for breast cancer that has spread to the liver, potentially slowing tumor growth.
What could go wrong: This is a very small pilot study with only 11 participants, so results may not apply to everyone. The combination of immunotherapy and radiation can cause serious side effects, and it is too early to know if it will be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 METASTATIC BREAST CARCINOMA METASTATIC CARCINOMA IN THE LIVER

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.